Ernie Toth joined Aquestive as Chief Financial Officer in December 2020. Prior to Aquestive, he was CFO of EHE Health, a national preventive health, primary care, and telehealth network owned by Summit Partners and DW Healthcare Partners. From January 2016 to December 2016, he was Chief Financial Officer of ArisGlobal, an end-to-end drug development platform, and from January 2015 to December 2015, Global Chief Financial Officer of Synowledge, a global life sciences solutions company providing drug safety, regulatory affairs, and IT services to pharmaceutical, biotechnology, and medical device companies.
At both ArisGlobal and Synowledge, he led Finance, HR, IT, Legal, and Commercial Operations during periods of high growth and the sale of Synowledge to Bioclinica. Ernie was Chief Financial Officer from 2011 to 2013 of JHP Pharmaceuticals, a PE-owned (Morgan Stanley Private Investments) integrated specialty healthcare company that develops, manufactures, and sells branded and generic aseptic injectable pharmaceuticals and provides contract manufacturing services for global pharmaceutical companies. As CFO, Ernie provided financial and operational leadership through nine new product launches, 17 ANDA filings, a BARDA award, clinical trials, and the sale to Warburg Pincus in 2012.
From 2014 until its sale to a strategic buyer in 2017, Ernie was a member of the Board of Directors of Eska, a leading Canadian beverage company owned by Morgan Stanley Private Investments. His prior experience includes senior financial leadership positions at Valeritas, Pharmaceutical Formulations, and World Power Technologies. He spent 15 years in various financial positions at MacAndrews & Forbes, the investment company owned by Ronald O. Perelman.
Ernie holds an MBA from Pace University, a BS in Accounting from Shippensburg University of Pennsylvania, and is a CPA in the State of New York.
What is Ernest Toth Jr's net worth?
The estimated net worth of Ernest Toth Jr is at least $1.46 million as of March 10th, 2026. Jr owns 376,112 shares of Aquestive Therapeutics stock worth more than $1,459,315 as of March 24th. This net worth approximation does not reflect any other investments that Jr may own. Additionally, Jr receives an annual salary of $667,190.00 as CFO at Aquestive Therapeutics. Learn More about Ernest Toth Jr's net worth.
How old is Ernest Toth Jr?
Jr is currently 65 years old. There are 2 older executives and 5 younger executives at Aquestive Therapeutics. The oldest executive at Aquestive Therapeutics is Ms. Lori J. Braender BSBA, Esq., J.D., Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary, who is 68 years old. Learn More on Ernest Toth Jr's age.
What is Ernest Toth Jr's salary?
As the CFO of Aquestive Therapeutics, Inc., Jr earns $667,190.00 per year. There are 3 executives that earn more than Jr. The highest earning executive at Aquestive Therapeutics is Mr. Daniel Barber, CEO, President & Director, who commands a salary of $1,060,000.00 per year. Learn More on Ernest Toth Jr's salary.
How do I contact Ernest Toth Jr?
Has Ernest Toth Jr been buying or selling shares of Aquestive Therapeutics?
Over the course of the past ninety days, Ernest Toth Jr has sold $242,919.18 in Aquestive Therapeutics stock. Most recently, A Ernest Toth, Jr. sold 58,254 shares of the business's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $4.17, for a transaction totalling $242,919.18. Following the completion of the sale, the chief financial officer now directly owns 376,112 shares of the company's stock, valued at $1,568,387.04. Learn More on Ernest Toth Jr's trading history.
Who are Aquestive Therapeutics' active insiders?
Are insiders buying or selling shares of Aquestive Therapeutics?
In the last year, insiders at the sold shares 15 times. They sold a total of 672,460 shares worth more than $3,342,230.34. The most recent insider tranaction occured on March, 10th when insider Peter E Boyd sold 29,814 shares worth more than $124,324.38. Insiders at Aquestive Therapeutics own 8.4% of the company.
Learn More about insider trades at Aquestive Therapeutics. Information on this page was last updated on 3/10/2026.
